The primary mechanism of CRPC progression involves cancer cells utilizing androgenic precursors from the blood or synthesizing de novo testosterone through the upregulation of steroidogenic enzymes, including Cyp17A1, AKR1C3, and 5α-reductase. This evidence concerns the gene AKR1C3 and cancer.